Biotech Stocks Drop After Troubling CRISPR Study, but Gene Editing Is Still the Future
On Monday, the world of science awoke to news that suddenly cast uncomfortable doubt on many of the past five years’ major breakthroughs: A new paper had identified a possible barrier to using the revolutionary gene-editing tool CRISPR-Cas9 in humans. The news incited a temporary hysteria that sent the stocks of all…
from Gizmodo http://ift.tt/2CHxzir
via IFTTT